#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Scleroderma associated digital ulcer Chondrodystrophy Neurofibroma Pemphigus Bronchiolitis Severe myoclonic epilepsy of infancy Ovarian epithelial cancer Glomerulonephritis chronic Cervix carcinoma Astrocytoma Muscular dystrophy Urea cycle disorder B-cell small lymphocytic lymphoma refractory Bone marrow disorder Central nervous system neoplasm More trials…

    Learn about Rare Diseases

    Hereditary angioedema Retinoblastoma – Life with Disease Mantle cell lymphoma – Trials in Disease Testicular leiomyosarcoma – Treatment Arterial tortuosity syndrome Behcet’s syndrome – Treatment Myxofibrosarcoma Factor VIII deficiency – Life with Disease Primary biliary cholangitis Haemophilia A with anti factor VIII – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Emtricitabine Lenacapavir Sodium Esketamine Tazobactam Sodium Abacavir Sulfate Ethambutol Hydrochloride Ly3556050 Gadobenate Dimeglumine Bi-1808 Zasocitinib Pancreas Powder Meropenem Trihydrate Abrocitinib OXYBUTYNIN HYDROCHLORIDE Anifrolumab Alx148 Tertomotide Triptorelin Pamoate Phleum Pratense (225) Soft Paraffin And Fat Products More therapies…

    Learn about Your Condition

    Hand dermatitis Lung adenocarcinoma stage IV Anal cancer Pneumothorax Choroidal dystrophy Optic ischaemic neuropathy Latent tuberculosis Synovial sarcoma metastatic Fallopian tube cancer stage IV Myocarditis post infection Cushing's syndrome Pancreatic carcinoma stage IV Complex regional pain syndrome Fabry's disease Depression More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hidradenitis

  • Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

    Not recruiting

    4 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Spesolimab
    Austria Belgium Bulgaria Czechia Denmark Finland +8

  • Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
    Germany Greece Poland

  • Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Bulgaria Croatia Czechia Finland +12

  • Study on Izokibep for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Izokibep
    France Germany Hungary Poland Spain

  • Study on the Effectiveness and Safety of SAR444656 for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Sar444656
    Germany Greece Poland Spain

  • Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Austria Belgium Czechia France Germany Greece +3
Previous Page
1 … 5 6 7 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!